至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Loss of a Negative Feedback Loop between IRF8 and AR Promotes Prostate Cancer Growth and Enzalutamide Resistance

Cancer Res. 2020; 
Hongxi Wu, Linjun You, Yan Li, Zhili Zhao, Guangjiang Shi, Zhen Chen, Zhuo Wang, Xianjing Li, Shijia Du, Wanli Ye, Xiaofang Gao, Jingjing Duan, Yan Cheng, Weiyan Tao, Jinsong Bian, Jin-Rong Zhou, Qingyi Zhu, Yong Yang
Products/Services Used Details Operation
Plasmid DNA Preparation … Plasmids including pcDNA3 (Vector), pcDNA3-hIRF8 (IRF8), pcDNA3-hAR (AR), 125 containing the whole CDS domains were constructed by Genscript (Nanjing, China); 126 double luciferase reporter plasmid pEZX-FR03-hIRF8-luc, carrying the IRF8 127 … Get A Quote

摘要

In incurable castration-resistant prostate cancer (CRPC), resistance to the novel androgen receptor (AR) antagonist enzalutamide is driven mainly by AR overexpression. Here we report that the expression of interferon regulatory factor 8 (IRF8) is increased in primary prostate cancer but decreased in CRPC compared with normal prostate tissue. Decreased expression of IRF8 positively associated with CRPC progression and enzalutamide resistance. IRF8 interacted with AR and promoted its degradation via activation of the ubiquitin/proteasome systems. Epigenetic knockdown of IRF8 promoted AR-mediated prostate cancer progression and enzalutamide resistance and . Furthermore, IFNα increased expression of IRF8 and impr... More

关键词